Stock Market Update - January 20, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. CRVS - Corvus Pharmaceuticals, Inc.
Price: $21.41 | Change: +165.96% ($13.36)
CRVS rocketed up by an impressive 165.96% recently, thanks to exciting news about its lead drug candidate, soquelitinib. The company reported positive Phase 1 clinical trial results for the drug, which is being developed to treat atopic dermatitis (commonly known as eczema). A significant 75% of patients achieved a 75% improvement in their condition (EASI 75), far outpacing the placebo group where only 20% saw similar results.
These promising findings suggest soquelitinib could be an effective oral treatment, even for patients who haven't responded to other systemic therapies. Corvus Pharmaceuticals plans to advance the drug into Phase 2 trials in early 2026, with its CEO expressing high confidence in its potential to become a leading therapy. While a concurrent stock offering was also announced to fund future development, the market's initial strong reaction was clearly ignited by the compelling clinical data.
2. ACRS - Aclaris Therapeutics, Inc.
Price: $4.43 | Change: +69.08% ($1.81)
ACRS saw a remarkable 69.08% gain recently, thanks to exciting news from Aclaris Therapeutics. The surge was primarily driven by very positive interim results from an early-stage clinical trial for their new drug candidate, ATI-052.
This novel bispecific antibody, designed for immuno-inflammatory diseases, showed a strong safety profile and impressive effectiveness in suppressing key pathways related to conditions like atopic dermatitis and asthma. These encouraging findings allowed Aclaris to accelerate its development plans, quickly moving ATI-052 into later-stage trials.
What makes this particularly interesting is the speed at which Aclaris is progressing. They've already launched a new trial for atopic dermatitis patients and plan another for asthma, both within the first quarter of 2026. This rapid advancement, combined with the drug's potential as a "best-in-class" treatment, was a major catalyst for investor excitement.
3. RAPT - RAPT Therapeutics, Inc.
Price: $57.57 | Change: +64.02% ($22.47)
RAPT saw its stock price rocket by an impressive 64% in late January 2026. This significant surge followed the announcement that pharmaceutical powerhouse GSK would acquire RAPT Therapeutics for $2.2 billion in an all-cash transaction. The deal valued RAPT at $58 per share, marking a substantial premium over its prior trading price.
This acquisition is a strategic move for GSK to bolster its immunology portfolio, with the centerpiece being RAPT's lead drug candidate, ozureprubart. This experimental allergy treatment is currently in advanced clinical trials and is designed to protect against food allergens.
What makes this drug particularly interesting is its potential for a once-quarterly dosing schedule. This convenient administration could be a significant advantage over existing treatments that require more frequent doses, potentially expanding access and improving quality of life for many patients.
4. SGN - Signing Day Sports, Inc.
Price: $0.2188 | Change: +61.00% ($0.0829)
SGN saw its stock jump an impressive 61.00% recently, and the reason points to a major strategic pivot. Signing Day Sports is undergoing a proposed business combination with BlockchAIn Digital Infrastructure, a move that aims to transform SGN into a cash-generating platform focused on the booming AI digital infrastructure space.
This deal caught investors' eyes because BlockchAIn brings solid financials, having reported nearly $23 million in revenue and $5.7 million in net income in 2024. They also operate a 40-megawatt data center with plans for significant expansion. Essentially, Signing Day Sports is looking to reorient itself squarely into the artificial intelligence and high-performance computing infrastructure sector.
The news sparked considerable investor optimism, especially with the deal anticipated to close in early 2026. This serves as a clear example of how a strategic announcement, promising a complete shift in business focus towards a high-growth sector like AI, can dramatically impact a stock's performance.
5. YOUL - Youlife Group Inc. American Depositary Shares
Price: $1.48 | Change: +59.93% ($0.5546)
YOUL recently saw an impressive surge, rocketing by nearly 60% around January 21, 2026, after a previous period of decline. This significant rebound for Youlife Group Inc. (YOUL:NASDAQ) was primarily driven by a key strategic partnership announcement.
The company revealed a joint venture with Sealand Maritime Service Co., Ltd. to establish a new talent ecosystem specifically for high-end cruise tourism services. Youlife Group, a leading blue-collar lifetime service provider in China, known for its vocational education, HR recruitment, and employee management, is now expanding these comprehensive offerings into this specialized sector.
What makes this particularly interesting is how this collaboration aligns directly with Youlife's mission to empower blue-collar workers through skill improvement and career development. Despite earlier news of potential acquisitions causing a stock dip in December, the market clearly reacted positively to the Sealand Maritime partnership, fueling these substantial recent gains.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.